All of DSpace

Browsing by Subject "Parkinson Disease"

Now showing items 1-20 of 32

    • Activation of FADD-Dependent neuronal death pathways as a predictor of pathogenicity for LRRK2 mutations 

      Melachroinou K., Leandrou E., Valkimadi P.-E., Memou A., Hadjigeorgiou G., Stefanis L., Rideout H.J. (2016)
      Background Despite the plethora of sequence variants in LRRK2, only a few clearly segregate with PD. Even within this group of pathogenic mutations, the phenotypic profile can differ widely. Objective We examined multiple ...

    • Applications of nanotechnology in diagnostics and therapeutics of Alzheimer's and Parkinson's disease 

      Soursou G., Alexiou A., Ashraf G.M., Siyal A.A., Mushtaq G., Kamal M.A. (2015)
      In this paper, an extended review analysis has been presented concerning the developments in brain drug delivery through new and efficient applications of nanotechnology. Modern nanotechnological approaches for the diagnosis ...

    • Assessment of TREM2 rs75932628 variant’s association with Parkinson’s disease in a Greek population and Meta-analysis of current data 

      Dardiotis E., Rikos D., Siokas V., Aloizou A.-M., Tsouris Z., Sakalakis E., Brotis A.G., Bogdanos D.P., Hadjigeorgiou G.M. (2021)
      Background: Α number of genetic variants are considered to confer susceptibility to Parkinson’s disease (PD). Rs75392628 (R47H), a rare variant of TREM2 gene, has been linked to PD, although its role on PD remains conflicting. ...

    • Association between white matter lesions and Parkinson’s disease: an impact on Postural/Gait difficulty phenotype and cognitive performance 

      Sinani O., Dadouli K., Ntellas P., Kapsalaki E.Z., Vlychou M., Raptis D.G., Marogianni C., Markou K., Dardiotis E., Xiromerisiou G. (2022)
      Background: White matter hyperintensities (WMHs) may be observed on Magnetic Resonance Imaging (MRI) in patients with Parkinson disease with or without vascular risk factors. Whether WMHs may influence motor and non-motor ...

    • The beneficial effects of computer-based cognitive training in parkinson's disease: A systematic review 

      Nousia A., Martzoukou M., Tsouris Z., Siokas V., Aloizou A.-M., Liampas I., Nasios G., Dardiotis E. (2021)
      Background: Cognitive dysfunction is one of the most prevalent non-motor aspects of Parkinson's disease (PD). The present review focuses on published studies investigating the effect of computer-based cognitive training ...

    • CD33 rs3865444 as a risk factor for Parkinson's disease 

      Siokas V., Arseniou S., Aloizou A.-M., Tsouris Z., Liampas I., Sgantzos M., Liakos P., Bogdanos D.P., Hadjigeorgiou G.M., Dardiotis E. (2021)
      Background: Alzheimer's (AD) and Parkinson's diseases (PD) share a few elements of their clinical, pathological and genetic backgrounds. The CD33 rs3865444 has emerged as a strong genetic locus associated with AD through ...

    • Construction of joint confidence regions for the optimal true class fractions of Receiver Operating Characteristic (ROC) surfaces and manifolds 

      Bantis L.E., Nakas C.T., Reiser B., Myall D., Dalrymple-Alford J.C. (2017)
      The three-class approach is used for progressive disorders when clinicians and researchers want to diagnose or classify subjects as members of one of three ordered categories based on a continuous diagnostic marker. The ...

    • Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study 

      Balomenos V., Bounou L., Charisis S., Stamelou M., Ntanasi E., Georgiadi K., Mourtzinos I., Tzima K., Anastasiou C.A., Xiromerisiou G., Maraki M., Yannakoulia M., Kosmidis M.H., Dardiotis E., Hadjigeorgiou G., Sakka P., Stefanis L., Scarmeas N. (2022)
      The aim of the present study was to investigate the association of the inflammatory potential of diet with prodromal Parkinson's disease (pPD) probability and incidence among community-dwelling older individuals without ...

    • The Effects of Action Observation Therapy as a Rehabilitation Tool in Parkinson’s Disease Patients: A Systematic Review 

      Giannakopoulos I., Karanika P., Papaxanthis C., Tsaklis P. (2022)
      During Action Observation (AO), patients observe human movements that they then try to imitate physically. Until now, few studies have investigated the effectiveness of it in Parkinson’s disease (PD). However, due to the ...

    • Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study 

      Wang L., Heckman M.G., Aasly J.O., Annesi G., Bozi M., Chung S.J., Clarke C., Crosiers D., Eckstein G., Garraux G., Hadjigeorgiou G.M., Hattori N., Jeon B., Kim Y.J., Kubo M., Lesage S., Lin J.J., Lynch T., Lichtner P., Mellick G.D., Mok V., Morrison K.E., Quattrone A., Satake W., Silburn P.A., Stefanis L., Stockton J.D., Tan E.K., Toda T., Brice A., Van Broeckhoven C., Uitti R.J., Wirdefeldt K., Wszolek Z., Xiromerisiou G., Maraganore D.M., Gasser T., Krüger R., Farrer M.J., Ross O.A., Sharma M. (2017)
      A recent study MacLeod et al. has shown that an interaction between variants at the LRRK2 and PARK16 loci influences risk of development of Parkinson's disease (PD). Our study examines the proposed interaction between LRRK2 ...

    • Frailty and Prodromal Parkinson's Disease: Results from the HELIAD Study 

      Ntanasi E., Maraki M., Yannakoulia M., Stamelou M., Xiromerisiou G., Kosmidis M.H., Dardiotis E., Hadjigeorgiou G., Sakka P., Gargalionis A., Patas K., Chatzipanagiotou S., Charisis S., Stefanis L., Scarmeas N. (2021)
      Background: To investigate the association between frailty, Parkinson's disease (PD), and the probability of prodromal Parkinson's disease (prodromal PD) in Greek community-dwelling older individuals. Methods: Parkinson's ...

    • Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture 

      Chia R., Sabir M.S., Bandres-Ciga S., Saez-Atienzar S., Reynolds R.H., Gustavsson E., Walton R.L., Ahmed S., Viollet C., Ding J., Makarious M.B., Diez-Fairen M., Portley M.K., Shah Z., Abramzon Y., Hernandez D.G., Blauwendraat C., Stone D.J., Eicher J., Parkkinen L., Ansorge O., Clark L., Honig L.S., Marder K., Lemstra A., St George-Hyslop P., Londos E., Morgan K., Lashley T., Warner T.T., Jaunmuktane Z., Galasko D., Santana I., Tienari P.J., Myllykangas L., Oinas M., Cairns N.J., Morris J.C., Halliday G.M., Van Deerlin V.M., Trojanowski J.Q., Grassano M., Calvo A., Mora G., Canosa A., Floris G., Bohannan R.C., Brett F., Gan-Or Z., Geiger J.T., Moore A., May P., Krüger R., Goldstein D.S., Lopez G., Tayebi N., Sidransky E., Sotis A.R., Sukumar G., Alba C., Lott N., Martinez E.M.G., Tuck M., Singh J., Bacikova D., Zhang X., Hupalo D.N., Adeleye A., Wilkerson M.D., Pollard H.B., Norcliffe-Kaufmann L., Palma J.-A., Kaufmann H., Shakkottai V.G., Perkins M., Newell K.L., Gasser T., Schulte C., Landi F., Salvi E., Cusi D., Masliah E., Kim R.C., Caraway C.A., Monuki E.S., Brunetti M., Dawson T.M., Rosenthal L.S., Albert M.S., Pletnikova O., Troncoso J.C., Flanagan M.E., Mao Q., Bigio E.H., Rodríguez-Rodríguez E., Infante J., Lage C., González-Aramburu I., Sanchez-Juan P., Ghetti B., Keith J., Black S.E., Masellis M., Rogaeva E., Duyckaerts C., Brice A., Lesage S., Xiromerisiou G., Barrett M.J., Tilley B.S., Gentleman S., Logroscino G., Serrano G.E., Beach T.G., McKeith I.G., Thomas A.J., Attems J., Morris C.M., Palmer L., Love S., Troakes C., Al-Sarraj S., Hodges A.K., Aarsland D., Klein G., Kaiser S.M., Woltjer R., Pastor P., Bekris L.M., Leverenz J.B., Besser L.M., Kuzma A., Renton A.E., Goate A., Bennett D.A., Scherzer C.R., Morris H.R., Ferrari R., Albani D., Pickering-Brown S., Faber K., Kukull W.A., Morenas-Rodriguez E., Lleó A., Fortea J., Alcolea D., Clarimon J., Nalls M.A., Ferrucci L., Resnick S.M., Tanaka T., Foroud T.M., Graff-Radford N.R., Wszolek Z.K., Ferman T., Boeve B.F., Hardy J.A., Topol E.J., Torkamani A., Singleton A.B., Ryten M., Dickson D.W., Chiò A., Ross O.A., Gibbs J.R., Dalgard C.L., Traynor B.J., Scholz S.W., The American Genome Center (2021)
      The genetic basis of Lewy body dementia (LBD) is not well understood. Here, we performed whole-genome sequencing in large cohorts of LBD cases and neurologically healthy controls to study the genetic architecture of this ...

    • Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence from the COURAGE-PD Consortium 

      Grover S., Sreelatha A.A.K., Pihlstrom L., Domenighetti C., Schulte C., Sugier P.-E., Radivojkov-Blagojevic M., Lichtner P., Mohamed O., Portugal B., Landoulsi Z., May P., Bobbili D., Edsall C., Bartusch F., Hanussek M., Krüger J., Hernandez D.G., Blauwendraat C., Mellick G.D., Zimprich A., Pirker W., Tan M., Rogaeva E., Lang A., Koks S., Taba P., Lesage S., Brice A., Corvol J.-C., Chartier-Harlin M.-C., Mutez E., Brockmann K., Deutschländer A.B., Hadjigeorgiou G.M., Dardiotis E., Stefanis L., Simitsi A.M., Valente E.M., Petrucci S., Straniero L., Zecchinelli A., Pezzoli G., Brighina L., Ferrarese C., Annesi G., Quattrone A., Gagliardi M., Burbulla L.F., Matsuo H., Kawamura Y., Hattori N., Nishioka K., Chung S.J., Kim Y.J., Pavelka L., Van De Warrenburg B.P.C., Bloem B.R., Singleton A.B., Aasly J., Toft M., Guedes L.C., Ferreira J.J., Bardien S., Carr J., Tolosa E., Ezquerra M., Pastor P., Diez-Fairen M., Wirdefeldt K., Pedersen N.L., Ran C., Belin A.C., Puschmann A., Hellberg C., Clarke C.E., Morrison K.E., Krainc D., Farrer M.J., Kruger R., Elbaz A., Gasser T., Sharma M. (2022)
      Background and Objectives Considerable heterogeneity exists in the literature concerning genetic determinants of the age at onset (AAO) of Parkinson disease (PD), which could be attributed to a lack of well-powered replication ...

    • H. pylori and Parkinson's disease: Meta-analyses including clinical severity 

      Dardiotis E., Tsouris Z., Mentis A.-F.A., Siokas V., Michalopoulou A., Sokratous M., Dastamani M., Bogdanos D.P., Deretzi G., Kountouras J. (2018)
      The exact etiology of Parkinson's disease (PD) remains unclear. Some evidence supports Helicobacter pylori infection as a trigger or driving event, but detection and eradication of H. pylori are not part of PD management. ...

    • Higher probability of prodromal Parkinson disease is related to lower cognitive performance 

      Bougea A., Maraki M.I., Yannakoulia M., Stamelou M., Xiromerisiou G., Kosmidis M.H., Ntanasi E., Dardiotis E., Hadjigeorgiou G.M., Sakka P., Anastasiou C.A., Stefanis L., Scarmeas N. (2019)
      ObjectiveGiven the limited information on cognitive function before Parkinson disease (PD) clinical onset in the general population, we sought to assess prodromal PD (pPD) probability and relate it to detailed cognitive ...

    • Human coronaviruses in idiopathic Parkinson's disease: Implications of SARS-CoV-2's modulation of the host's transcriptome 

      Vavougios G.D. (2021)
      Objective: A recent study on the effects of SARS-CoV-2 infection on the host's transcriptome indicated the perturbation of several pathways associated with neurodegeneration, including but not limited to Parkinson's and ...

    • Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study 

      Vavougios G.D., Doskas T., Kormas C., Krogfelt K.A., Zarogiannis S.G., Stefanis L. (2018)
      Aim: The aim of our study is to phenotype PD motor progression, and to detect whether serum, cerebrospinal fluid (CSF), neuroimaging biomarkers and neuropsychological measures characterize PD motor progression phenotypes. ...

    • Ketogenic therapy for Parkinson's disease: A systematic review and synthesis without meta-analysis of animal and human trials 

      Grammatikopoulou M.G., Tousinas G., Balodimou C., Anastasilakis D.A., Gkiouras K., Dardiotis E., Evangeliou A.E., Bogdanos D.P., Goulis D.G. (2022)
      Objective: The aim of the present systematic review was to assess the efficacy of ketogenic therapy in Parkinson's disease (PD), using all available data from randomized controlled trials (RCTs) on humans and animal studies ...

    • Large-scale assessment of polyglutamine repeat expansions in Parkinson disease 

      Wang L., Aasly J.O., Annesi G., Bardien S., Bozi M., Brice A., Carr J., Chung S.J., Clarke C., Crosiers D., Deutschländer A., Eckstein G., Farrer M.J., Goldwurm S., Garraux G., Hadjigeorgiou G.M., Hicks A.A., Hattori N., Klein C., Jeon B., Kim Y.J., Lesage S., Lin J.-J., Lynch T., Lichtner P., Lang A.E., Mok V., Jasinska-Myga B., Mellick G.D., Morrison K.E., Opala G., PihlstrØm L., Pramstaller P.P., Park S.S., Quattrone A., Rogaeva E., Ross O.A., Stefanis L., Stockton J.D., Silburn P.A., Theuns J., Tan E.K., Tomiyama H., Toft M., Van Broeckhoven C., Uitti R.J., Wirdefeldt K., Wszolek Z., Xiromerisiou G., Yueh K.-C., Zhao Y., Gasser T., Maraganore D.M., Krüger R., Sharma M. (2015)
      Objectives: We aim to clarify the pathogenic role of intermediate size repeat expansions of SCA2, SCA3, SCA6, and SCA17 as risk factors for idiopathic Parkinson disease (PD). Methods: We invited researchers from the Genetic ...

    • Late life psychotic features in prodromal Parkinson's disease 

      Pachi I., Maraki M.I., Giagkou N., Kosmidis M.H., Yannakoulia M., Dardiotis E., Hadjigeorgiou G., Sakka P., Ntanasi E., Xiromerisiou G., Stamelou M., Scarmeas N., Stefanis L. (2021)
      Introduction: Some case series have suggested that psychotic features could occur even before the onset of motor symptoms of Parkinson's Disease (PD). Our aim was to investigate a possible association between psychotic ...